https://en.wikipedia.org/wiki/Veress_needle

A "small thing" that sells millions of units a year, supports the start of almost every laparoscopic surgery on the planet. The global Vires needle market is integrated within the overall laparoscopic puncture/entry system market. Its characteristics are extremely distinct:

• Low ASP + Extremely High Repeat Purchase Frequency = Growth driven by scale rather than single-product profit margins

The Three Forces Driving Growth

• Expansion of MIS penetration rate (particularly evident in emerging markets)
• Reuse → One-time irreversible migration
• Aging boosts the volume of minimally invasive surgeries for gallbladder/hernia/colon and rectal diseases

Three Major Macro Forces

The end of the era of reutilization is irreversible. Infection control lawsuits, Joint Commission aseptic audits, the logistical nightmare of tracking and cleaning a 2mm spring needle - even academic tertiary hospitals are now mostly switching to disposable products for routine cases. The remaining reusable sites are mainly found in public systems with extremely limited budgets or in resource-poor areas - this market segment is shrinking.

1. The narrative of safety continues to tighten.

Every case of "sudden major vascular death during routine diagnostic laparoscopy" appears in medical literature and court cases. Institutions such as ACOG have softened their language regarding the "Veress preferred" approach, clearly stating that the open/optical approach can be used as the first line of treatment for high-risk patients. The research system of ultrasound-guided pneumoperitoneum (USP) is also expanding - if real-time imaging becomes the standard, blind Veress puncture will lose its monopoly - but the needle itself may survive, merely becoming an execution component in the image-guided workflow (the needle doesn't need to know how you aim it).

1. The low-end premiumization path

Kipin has already become a commodity. The profit opportunity lies in the enhanced feature versions: integrated deep stop mechanism, RFID/UDI batch tracking (connected to the hospital consumables management system), and curve linkage automatic interpretation with the intelligent pneumoperitoneum machine. The winners do not engage in price wars to the end - they build a trust infrastructure: traceability, batch-level documentation, regulatory durability (MDR-ready CE, clean 510(k)).

Three Quick Judgments of Scenarios

• Baseline scenario (≈55%): Veress maintains its default position, optical method grows but remains a niche option → With a moderate increase in the total amount of MIS (±3–5% per year), prices are continuously suppressed by generic products
• Safety-driven shift (≈30%): The guideline officially places open/optical methods at the forefront for more than half of the cases → In developed markets, the Veress volume plateau even slows down, while in low-cost markets, it becomes stronger
• Technological leap (≈15%): Image guidance or robotic automatic approaches replace manual blind punctures → Veress regresses to the legacy/rescue role, and the category shrinks into a niche.

How Each Party is Arranging Things

Player Type: Strategy

• Domestic OEM Export Firms (such as Bor, Tianke, Zhichao, etc.): Secure the certification moat: MDR compliance CE + FDA 510(k) + ISO 13485 audit - Generic brands cannot cross this threshold
• Transnational Traditional Brands (Ethicon/CONMED/Teleflex): Secure clinical trust + sales relationship - The needle is often the "hook" for introducing the entire advanced puncture sheath system
• Comprehensive Medical Device Giants (Mindray, etc.): Secure product matrix bundling: The Vires needle serves as the entry-level SKU to be brought into the OR, followed by forceps/fixators/electrocoagulation in the complete consumables basket

In summary: The one-time Vires needle is essentially a "solution that waits to be eliminated" - ideally, humans should not need to perform blind punctures on the bellies of living people. However, until the ergonomics, cost, and training pipeline for the optical approach are completed as a replacement, this 1938 spring needle will still be the nameless opening line for almost every laparoscopic surgery on the planet. Its future is not determined by more attractive cutting edges or handles, but by when the surgical community collectively decides: "adequate" no longer equals "necessary".